{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:31:57Z","timestamp":1769124717975,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To compare baseline characteristics of patients with heart failure with reduced ejection fraction (HFrEF) initiated on sacubitril\/valsartan compared with patients continued on conventional heart failure (HF)-treatment in a European out-patient setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Between July 2016 and July 2019, ARIADNE enrolled 8787 outpatients aged \u226518\u2009years with HFrEF from 17 European countries. Choice of therapy was solely at the investigators\u2019 discretion. In total, 4173 patients were on conventional HF-treatment (non-S\/V group), while 4614 patients were on sacubitril\/valsartan either at enrolment or started sacubitril\/valsartan within 1 month of enrolment (S\/V group). Of these, 2108 patients started sacubitril\/valsartan treatment \u00b11\u2009month around enrolment [restricted S\/V (rS\/V) group]. The average age of the patients was 68\u2009years. Patients on S\/V were more likely to have New York Heart Association (NYHA) class III or IV symptoms (50.3%, 44.6%, 32.1% in rS\/V, S\/V, and non-S\/V, respectively) and had lower left ventricular ejection fraction (LVEF; 32.3%, 32.7%, and 35.4% in rS\/V, S\/V, and non-S\/V, respectively; P\u2009&amp;lt;\u20090.0001). The most frequently received HF treatments were angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker (ACEI\/ARB; \u223c84% in non-S\/V), followed by \u03b2-blockers (\u223c80%) and mineralocorticoid receptor antagonists (MRAs; 53%). The use of triple HF therapy (ACEI\/ARB\/angiotensin receptor neprilysin inhibitor with \u03b2-blockers and MRA) was higher in the S\/V groups than non-S\/V group (48.2%, 48.2%, and 40.2% in rS\/V, S\/V, and non-S\/V, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this large multinational HFrEF registry, patients receiving sacubitril\/valsartan tended to be younger with lower LVEF and higher NYHA class. Fewer than half of the patients received triple HF therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcab019","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T20:09:46Z","timestamp":1615579786000},"page":"469-477","source":"Crossref","is-referenced-by-count":12,"title":["Utilization of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry"],"prefix":"10.1093","volume":"8","author":[{"given":"Uwe","family":"Zeymer","sequence":"first","affiliation":[{"name":"Klinikum Ludwigshafen, Medizinische Klinik B and Institut f\u00fcr Herzinfarktforschung , Bremserstrasse 79 , 67063 Ludwigshafen-am-Rhein, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L","family":"Clark","sequence":"additional","affiliation":[{"name":"Castle Hill Hospital , Kingston Upon Hull, Castle Rd, Cottingham HU16 5JQ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ramon y Cajal Hospital , Ctra. de Colmenar Viejo km. 9,100 28034 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Henri Mondor Hospital , 1 Rue Gustave Eiffel, 94000 Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"Dro\u017cd\u017c","sequence":"additional","affiliation":[{"name":"Department Cardiology Medical University of Lodz , Poland 92-213 Lodz, Pomorska 251, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candida","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Hospital de Sao Francisco Xavier, Estrada Forte do Alto do Duque, 1449-005 , Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Unit of Cardiology, Karolinska Institutet and Karolinska University HospitalFoU Tema Hj\u00e4rta K\u00e4rl , Eugeniav\u00e4gen 3, Norrbacka, S1:02, 171 76 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Kalus","sequence":"additional","affiliation":[{"name":"GKM Gesellschaft f\u00fcr Therapieforschung mbH , Lessingstr. 14, 80336 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe C","family":"Ferber","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan I","family":"Hussain","sequence":"additional","affiliation":[{"name":"Arxx Therapeutics , Gaustadall\u00e9en 21, 0349 Oslo, Norway"},{"name":"Symbion Science Park , Fruebjergvej 3, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"Koch","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-6779","authenticated-orcid":false,"given":"Aldo P","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Associazione Nazionale Medici Cardiologi Ospedalieri Research Center , Via La Marmora 34, 50121 Florence, Italy"},{"name":"Maria Cecilia Hospital, GVM Care & Research , Via Corriera, 1, 48033 Cotignola RA, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"2022060701395572600_qcab019-B1","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2022060701395572600_qcab019-B2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/hrt.80.5.437","article-title":"Preventable causative factors leading to hospital admission with decompensated heart failure","volume":"80","author":"Michalsen","year":"1998","journal-title":"Heart"},{"key":"2022060701395572600_qcab019-B3","doi-asserted-by":"crossref","first-page":"e018243","DOI":"10.1136\/bmjopen-2017-018243","article-title":"Effect of cardiologist care on 6-month outcomes in patients discharged with heart failure: results from an observational study based on administrative data","volume":"7","author":"Avaldi","year":"2017","journal-title":"BMJ Open"},{"key":"2022060701395572600_qcab019-B4","author":"European Medicines Agency Assessment Report"},{"key":"2022060701395572600_qcab019-B5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2022060701395572600_qcab019-B6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ehf2.12569","article-title":"Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry","volume":"7","author":"Zeymer","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2022060701395572600_qcab019-B7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0895-4356(97)00306-5","article-title":"Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases","volume":"51","author":"van den Akker","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"2022060701395572600_qcab019-B8","first-page":"279","article-title":"Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy","volume":"7","author":"Briongos-Figuero","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2022060701395572600_qcab019-B9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12258","article-title":"Insights into implementation of sacubitril\/valsartan into clinical practice","volume":"5","author":"Martens","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2022060701395572600_qcab019-B10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022060701395572600_qcab019-B11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"2022060701395572600_qcab019-B12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00392-014-0743-x","article-title":"Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry","volume":"103","author":"von Scheidt","year":"2014","journal-title":"Clin Res Cardiol"},{"key":"2022060701395572600_qcab019-B13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/01.CIR.97.3.282","article-title":"Chronic heart failure in the United States: a manifestation of coronary artery disease","volume":"97","author":"Gheorghiade","year":"1998","journal-title":"Circulation"},{"key":"2022060701395572600_qcab019-B14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1136\/hrt.72.2_Suppl.S3","article-title":"Changing epidemiological features of cardiac failure","volume":"72","author":"Kannel","year":"1994","journal-title":"Br Heart J"},{"key":"2022060701395572600_qcab019-B15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.semnephrol.2006.05.006","article-title":"The interaction between heart failure and other heart diseases, renal failure, and anemia","volume":"26","author":"Silverberg","year":"2006","journal-title":"Semin Nephrol"},{"issue":"1","key":"2022060701395572600_qcab019-B16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1871525718666200506095537","article-title":"Sacubitril-valsartan improves anemia of cardiorenal syndrome","volume":"19","author":"Robles","year":"2020","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"2022060701395572600_qcab019-B17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jchf.2020.06.015","article-title":"Sacubitril\/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis","volume":"8","author":"Rohde","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2022060701395572600_qcab019-B18","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2022060701395572600_qcab019-B19","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2022060701395572600_qcab019-B20","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022060701395572600_qcab019-B21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/02813432.2017.1397253","article-title":"Adherence to guidelines in patients with chronic heart failure in primary health care","volume":"35","author":"Giezeman","year":"2017","journal-title":"Scand J Prim Health Care"},{"key":"2022060701395572600_qcab019-B22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2008.05.028","article-title":"Quality of care and outcomes among patients with heart failure and chronic kidney disease: a Get With the Guidelines-Heart Failure Program study","volume":"156","author":"Patel","year":"2008","journal-title":"Am Heart J"},{"key":"2022060701395572600_qcab019-B23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10557-019-06873-1","article-title":"\"Real World\" eligibility for sacubitril\/valsartan in unselected heart failure patients: data from the Swedish Heart Failure Registry","volume":"33","author":"Simpson","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022060701395572600_qcab019-B24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","article-title":"Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry","volume":"7","author":"Brunner-La Rocca","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2022060701395572600_qcab019-B25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurjhf\/hfn006","article-title":"Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden","volume":"11","author":"Dahlstrom","year":"2009","journal-title":"Eur J Heart Fail"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcab019\/38624544\/qcab019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/8\/4\/469\/43965494\/qcab019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/8\/4\/469\/43965494\/qcab019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T01:40:49Z","timestamp":1654566049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/8\/4\/469\/6174162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,3,16]]},"published-print":{"date-parts":[[2022,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcab019","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2021,3,16]]}}}